Methods and reagents for vaccination which generate a CD8 T cell immune response
AssigneeOxxon Pharmaccines, Ltd.
InventorsAndrew McMichael, Adrian V. S. Hill, Sarah C. Gilbert, Jörg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
Life of this patent
Estimating the term…
Abstract
New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
Claims20
A method for generating a CD8+ T cell immune response in a mammal against at least one target antigen, comprising administering to said mammal at least one dose of each of the following:
- (i) a priming composition comprising a source of one or more CD8+ T cell epitopes of the target antigen;
- and
- (ii) a boosting composition comprising a source of one or more CD8+ T cell epitopes of the target antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, wherein the source of CD8+ T cell epitopes is a non-replicating or replication-impaired recombinant poxvirus vector in the mammal;
- with the proviso that if the source of epitopes in (i) is a viral vector, the viral vector in (ii) is derived from a different virus.
A method for generating a CD8+ T cell immune response in a mammal against a pathogen or tumor, comprising administering to said mammal at least one dose of a recombinant protein or particle comprising at least one naturally occurring epitope or antigen of the pathogen or the tumor, followed by at least one dose of a recombinant MVA vector encoding the same epitope or antigen.
A method for generating a protective CD8+ T cell immune response against at least one target antigen in a mammal, comprising administering to said mammal at least one dose of each of the following:
- (i) a priming composition comprising a source of one or more CD8+ T cell epitopes of the target antigen;
- and
- (ii) a boosting composition comprising a source of one or more CD8+ T cell epitopes of the target antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, wherein the source of CD8+ T cell epitopes is a MVA vector;
- with the proviso that if the source of epitopes in (i) is a viral vector, the viral vector in (ii) is derived from a different virus.
A method for generating a CD8+ T cell immune response against a pathogen or tumor in a mammal, comprising administering to said mammal at least one dose of a recombinant protein or particle comprising at least one naturally occurring CD8+ T cell epitope or antigen of the pathogen or the tumor, followed by at least one dose of a pox virus encoding the same epitope or antigen, wherein the pox virus is recombinant non-replicating or replication-impaired in the mammal.
A method for generating a CD8+ T cell immune response against a pathogen or tumor in a mammal, comprising administering to said mammal at least one dose of a recombinant DNA plasmid encoding at least one naturally occurring epitope or antigen of the pathogen or the tumor, followed by at least one dose of a recombinant MVA vector encoding the same epitope or antigen.
A method for generating a CD8+ T cell immune response against malaria in a mammal, comprising administering to said mammal at least one dose of each of the following:
- (i) a priming composition comprising a source of one or more CD8+ T cell epitopes of malaria;
- and
- (ii) a boosting composition comprising a source of one or more CD8+ T cell epitopes of malaria, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, wherein the source of CD8+ T cell epitopes is a non-replicating or replication-impaired poxvirus vector in the mammal;
- with the proviso that if the source of epitopes in (i) is a viral vector, the viral vector in (ii) is derived from a different virus.
A method for generating a CD8+ T cell immune response against malaria in a mammal, comprising administering to said mammal at least one dose of each of the following:
- (i) a priming composition comprising a source of one or more CD8+ T cell epitopes of malaria;
- and
- (ii) a boosting composition comprising a source of one or more CD8+ T cell epitopes of malaria, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, wherein the source of CD8+ T cell epitopes is a MVA vector;
- with the proviso that if the source of epitopes in (i) is a viral vector, the viral vector in (ii) is derived from a different virus.
A method for generating a CD8+ T cell immune response in a primate against at least one target antigen, comprising administering to said primate at least one dose of each of the following:
- (i) a priming composition comprising a source of one or more CD8+ T cell epitopes of the target antigen;
- and
- (ii) a boosting composition comprising a source of one or more CD8+ T cell epitopes of the target antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, wherein the source of CD8+ T cell epitopes is a non-replicating or replication-impaired recombinant poxvirus vector in the primate;
- with the proviso that if the source of epitopes in (i) is a viral vector, the viral vector in (ii) is derived from a different virus.
Dependencies are inferred from the claim text.